# Zoonotic Disease Diagnostic Testing: Sensitivity, Specificity, and Interpretation


## Key Takeaways

- Zoonotic diagnostic test interpretation necessitates understanding sensitivity (true positive rate) and specificity (true negative rate), as no test is perfect; low sensitivity tests miss infections, while low specificity tests yield false positives, particularly problematic in low-prevalence populations.
- Bayesian reasoning is critical, formally combining the pre-test probability (derived from species, geography, exposure, and clinical signs) with test likelihood ratios to establish a post-test probability of infection, moving beyond single test results to actionable conclusions.
- Test timing is paramount, as serological assays are unreliable in the acute phase (window period) before antibody production, while molecular methods (e.g., PCR) depend on active shedding and sample quality, requiring careful consideration of the infection stage.
- Confirmatory testing with a different biological principle is essential when screening results are discordant with clinical suspicion or when the consequences of a false positive are severe, aiming to reduce false positives while preserving screening sensitivity.
- Test selection and interpretation must be adapted across species due to variations in immunoglobulin responses and cross-reactivity, and for specific pathogens like *Coxiella burnetii*, limited test sensitivity necessitates ongoing biosecurity measures even with negative results.
- Documenting test rationale, platform, interpretation, and actions taken is crucial for clinical reasoning, public health reporting, and One Health coordination, with communication to owners emphasizing test limitations and potential human health implications.

---

Veterinary clinicians increasingly face diagnostic decisions in which the patient is an animal but the test result carries consequences for human health. Brucellosis, Q fever, toxoplasmosis, fascioliasis, and hepatitis E virus infection each present with non-specific clinical signs in reservoir or accidental hosts, and each requires a testing strategy that accounts for the performance characteriztics of available assays and the prevalence of disease in the source population. This article provides a framework for selecting and interpreting diagnostic tests for zoonotic diseases, with emphasis on sensitivity, specificity, and Bayesian reasoning. It serves veterinary researchers and clinicians who must move beyond a single test result to a defensible probability statement about infection status.

The central problem is that no zoonotic diagnostic test is perfect. Serological assays may fail to detect early infection, cross-react with related organizms, or remain positive long after the infectious risk has resolved. Molecular methods offer high analytical sensitivity but depend on sample quality, timing relative to shedding, and the genetic stability of the target. The clinician who understands these limitations can combine test results with prior probability to reach clinically actionable conclusions. The clinician who does not will misinterpret both positive and negative results, with consequences for animal management, human exposure, and public health reporting.

This article addresses the conceptual foundations of test interpretation, the practical application of sensitivity and specificity in zoonotic disease diagnosis, and the structured reasoning required when test performance is imperfect. The framework applies across species and across the major classes of zoonotic pathogens, with specific examples drawn from the published literature on coxiellosis, brucellosis, toxoplasmosis, fascioliasis, and hepatitis E.

## At a Glance

| Parameter | Clinical Relevance | Interpretation Guidance |
|---|---|---|
| Sensitivity | Probability that a test detects disease when infection is present | Low sensitivity tests miss early or low-burden infections, negative results do not exclude disease |
| Specificity | Probability that a test is negative when infection is absent | Low specificity produces false positives, problematic in low-prevalence populations |
| Prior probability | Estimated prevalence of infection before testing | Derived from species, geographic location, exposure history, and clinical signs |
| Positive predictive value | Probability of infection given a positive test | Falls as prevalence falls, a positive result in a low-risk animal may be less informative than a negative result in a high-risk animal |
| Negative predictive value | Probability of no infection given a negative test | Rises as prevalence falls, useful for ruling out disease in low-risk populations |
| Bayesian reasoning | Formal combination of prior probability with test likelihood ratios | Required when no single test has both high sensitivity and high specificity |
| Test timing | Phase of infection relative to exposure | Antibody tests are unreliable in the acute phase, antigen and molecular tests depend on active shedding |
| Confirmatory testing | Second assay with different biological basis | Recommended when the first result is discordant with clinical suspicion or when consequences of a false result are severe |

## Test Performance Fundamentals

Sensitivity and specificity are fixed properties of a test applied to a defined population, but they are not immutable constants. They vary with disease stage, pathogen strain, sample type, laboratory technique, and the reference standard against which the test was validated. A polymerase chain reaction assay validated on animals with acute shedding may perform differently in chronically infected carriers with intermittent organizm release. An enzyme-linked immunosorbent assay validated in a high-prevalence research herd may have different operating characteriztics in a low-prevalence commercial population. The clinician must ask also what the test is, but how it was validated and against which reference standard.

The distinction between analytical and clinical sensitivity matters in zoonotic testing. Analytical sensitivity refers to the lowest amount of target the assay can detect. Clinical sensitivity refers to the proportion of infected animals correctly identified. An assay with excellent analytical sensitivity may have poor clinical sensitivity if the target is not present in the sampled matrix at the time of collection. For Coxiella burnetii, available diagnostic tests have limited sensitivity, and this limitation complicates both individual animal diagnosis and herd-level management decisions [Plummer et al., consensus statement on Coxiella burnetii management](https://pubmed.ncbi.nlm.nih.gov/30084178/). The organizm is shed intermittently in birth products, vaginal mucus, feces, and milk, so a single negative polymerase chain reaction result from one sample type does not exclude active shedding.

Specificity problems arise from antigenic cross-reactivity among related organizms. Brucella species share surface antigens with other Gram-negative bacteria, and serological cross-reactions have long complicated diagnosis in both animals and humans. The clinical presentation of human brucellosis is notoriously non-specific, and fewer than 10% of cases may be clinically recognized, which means that diagnostic testing must be applied with a high index of suspicion instead of as a routine screen [Mantur et al., review of human brucellosis features](https://pubmed.ncbi.nlm.nih.gov/17901634/). In veterinary populations, vaccination with some Brucella strains can produce serological responses that are difficult to distinguish from field infection, further reducing test specificity in vaccinated herds.

## Likelihood Ratios and Bayesian Reasoning

Bayesian reasoning formalizes what experienced clinicians do intuitively. The post-test probability of disease depends on the pre-test probability and the likelihood ratio of the test result. The positive likelihood ratio is sensitivity divided by (1 minus specificity). The negative likelihood ratio is (1 minus sensitivity) divided by specificity. A test with a positive likelihood ratio above 10 substantially increases post-test probability, while a negative likelihood ratio below 0.1 substantially decreases it. Tests with likelihood ratios closer to 1.0 add little diagnostic information regardless of the result.

The pre-test probability is the clinician's estimate of infection prevalence in the specific animal or population before testing. This estimate draws on species, geographic origin, management system, exposure history, and clinical signs. In a dairy herd with an ongoing abortion storm and known Q fever risk factors, the pre-test probability for Coxiella burnetii is high, and even a test with modest sensitivity can be diagnostically useful when positive. In a closed herd with no reproductive disease and no contact with small ruminants, the pre-test probability is low, and a positive serological result is more likely to be a false positive than a true infection.

The practical consequence is that the same test result carries different meaning in different populations. A positive brucellosis serology in a cow from a certified-free herd requires confirmatory testing and careful interpretation, because the pre-test probability is very low. The same result in a cow from an endemic region with a history of abortion is far more likely to represent true infection. The clinician should estimate pre-test probability explicitly, document the reasoning, and choose tests whose likelihood ratios are sufficient to move that probability across the clinical threshold for action.

## Test Timing and the Window Period

Every zoonotic infection has a temporal sequence of diagnostic detectability. In the acute phase, before the adaptive immune response has produced measurable antibody, serological tests are negative. Antigen detection and molecular methods may be positive if the organizm or its nucleic acid is present in blood, feces, or other samples. As the infection progresses, antibody titers rise and molecular signals may decline. In chronic or latent infection, antibody tests are typically positive while molecular tests may be negative or intermittently positive.

For Fasciola infection in humans, antibody testing is the only diagnostic tool available early in the infection, while serology and stool microscopy become helpful in chronic forms [Caravedo and Cabada, review of human fascioliasis](https://pubmed.ncbi.nlm.nih.gov/33273878/). The same principle applies in animal hosts. A negative antibody test in an animal tested within days of exposure does not exclude infection, and a negative fecal examination in chronic fascioliasis does not exclude the presence of adult flukes. The clinician must match the test to the phase of infection, and when the phase is uncertain, must either repeat testing after an appropriate interval or use a test that targets a different biological analyte.

For Toxoplasma gondii, the distinction between acute and chronic infection has direct public health consequences. Serological assays are the most commonly used diagnostic methods, but differentiating between acute and chronic phases remains a challenge [Ybañez et al., review of toxoplasmosis serodiagnosis](https://pubmed.ncbi.nlm.nih.gov/32457848/). IgM and IgG patterns are used in human medicine to estimate the timing of infection, but the kinetics of these antibodies vary between individuals and between host species. In veterinary practice, the question is often not whether the animal is infected, but whether the infection is newly acquired and therefore associated with active shedding of oocysts or with congenital transmission risk.

## Choosing Among Test Platforms

The major test platforms for zoonotic diseases are culture, molecular amplification, antigen detection, and serology. Culture provides definitive proof of infection but is slow, requires specialized laboratory capacity, and poses an infection risk to laboratory personnel. Molecular methods such as polymerase chain reaction offer rapid turnaround and high analytical sensitivity, but they require that the organizm or its nucleic acid be present in the sample at the time of collection. Antigen detection tests are rapid and inexpensive but may lack sensitivity in low-burden infections. Serology detects the host response instead of the organizm, which makes it useful across a longer time window but subject to the limitations of antibody kinetics and cross-reactivity.

The choice among platforms depends on the clinical question. For an acutely ill animal with suspected bacteremia, blood culture or molecular testing is appropriate. For a herd investigation of reproductive disease, serology may be the most practical initial screen, with molecular testing of abortion material for confirmation. For a pre-purchase or pre-breeding screen in a low-prevalence population, a highly specific test is needed to avoid false positives that would disrupt trade or breeding plans. International standards for animal health and trade-related disease control, such as those published by the World Organization for Animal Health, provide guidance on which tests are acceptable for specific purposes and how results should be interpreted in the context of official disease status [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/).

## The Role of Confirmatory Testing

When a screening test returns a positive result in a low-prevalence population, or when the result is discordant with clinical suspicion, confirmatory testing with a different biological principle is indicated. The confirmatory test should have high specificity and should not share the same failure mode as the screening test. If the screening test is an enzyme-linked immunosorbent assay that detects antibody, the confirmatory test might be a western blot that detects antibody against specific antigens, or a molecular test that detects the organizm directly. The goal is to reduce the probability of a false positive result while preserving the sensitivity of the screening process.

Confirmatory testing is particularly important when the consequences of a false positive are severe. A false positive brucellosis result can trigger quarantine, depopulation, and trade restrictions. A false positive Coxiella burnetii result can lead to unnecessary biosecurity measures and anxiety among farm workers. The consensus statement on Coxiella burnetii management emphasizes that the limited sensitivity of available tests, combined with

## Interpreting Results in the Individual Patient

A positive or negative test result acquires clinical meaning only when placed in the context of the patient's exposure history, clinical signs, and the prior probability of disease. The same assay used for herd screening may be inappropriate for confirming a diagnosis in a single febrile animal, and the interpretive framework must shift accordingly.

For zoonoses with non-specific clinical presentations, such as brucellosis, the diagnostic challenge is compounded by the fact that fewer than 10% of human cases may be clinically recognized, and the same is true in animal hosts where abortion storms or orchitis may be the only visible manifestation [Review of clinical and laboratory features of human brucellosis](https://pubmed.ncbi.nlm.nih.gov/17901634/). In an individual animal with a compatible history, a positive screening test should prompt confirmatory testing instead of immediate action. In a herd context, the same positive result may trigger regulatory notification and movement restrictions before confirmation, depending on the agent and jurisdiction.

The decision to treat, isolate, or cull based on a single test result depends on the consequences of a false positive versus a false negative. For a zoonotic agent with high human health consequences, such as *Coxiella burnetii*, the cost of a false negative is the continued risk of aerosolized transmission to farm workers and veterinary personnel. The consensus statement on coxiellosis management notes that available diagnostic tests have limited sensitivity, which complicates both individual animal diagnosis and herd-level control [Management of Coxiella burnetii infection in livestock populations and](https://pubmed.ncbi.nlm.nih.gov/30084178/). When sensitivity is known to be imperfect, a negative result cannot exclude infection, and risk mitigation must proceed regardless of test outcome.

## Species and Production System Modifications

Test selection and interpretation are not transferable across species without adjustment. Serological assays validated in cattle may perform differently in goats, sheep, or camelids due to differences in immunoglobulin responses, cross-reacting antibodies, and the timing of seroconversion relative to exposure.

In ruminant production systems, abortion investigation protocols typically sequence testing based on the most likely agents for the species and region. For *Coxiella burnetii*, the organizm's ability to aerosolize easily and its low infectious dose make it a priority consideration in abortion outbreaks, particularly when multiple animals abort over a short period [Management of Coxiella burnetii infection in livestock populations and](https://pubmed.ncbi.nlm.nih.gov/30084178/). The diagnostic approach in a sheep flock differs from that in a dairy herd because of differences in management, the timing of the lambing season, and the potential for human exposure during lambing assistance.

For hepatitis E virus, the zoonotic transmission cycle involves swine as a reservoir host, and testing strategies differ between the pig population and human cases [Molecular biology and pathogenesis of hepatitis E virus](https://pubmed.ncbi.nlm.nih.gov/19208971/). In pigs, infection is typically subclinical and testing is used for surveillance and research instead of individual diagnosis. In humans, the diagnosis relies on serology and molecular testing, and the interpretation of a positive result depends on whether the patient has travelled to an endemic area or has had contact with pigs or pork products.

The availability of point-of-care tests also varies by species and setting. In companion animal practice, in-clinic serological tests for *Toxoplasma gondii* are widely used, but the interpretation of IgM and IgG results requires care because the differentiation between acute and chronic phases of infection remains a challenge with current serodiagnostic approaches [Review on the Current Trends of Toxoplasmosis Serodiagnosis in](https://pubmed.ncbi.nlm.nih.gov/32457848/). In food animal practice, testing is more likely to be performed at regional or national laboratories, and the turnaround time becomes a factor in clinical decision-making.

## A Structured Approach to Test Selection

The following framework can be applied when a zoonotic infection is suspected. The sequence is designed to move from risk assessment to test selection to interpretation, with explicit decision points at each stage.

| Step | Question to Answer | Information Required | Decision Point |
|------|-------------------|---------------------|----------------|
| 1 | What is the exposure history? | Species, source, travel, contact with wildlife, occupational exposure | Determines which agents are plausible |
| 2 | What is the clinical presentation? | Acute versus chronic, organ system involved, reproductive signs | Narrows the differential and informs test timing |
| 3 | What is the prior probability? | Regional prevalence, herd history, season, vaccination status | Determines whether screening or confirmatory testing is appropriate |
| 4 | Which test platform is available? | In-clinic versus reference laboratory, serology versus PCR, cost, turnaround | Determines what can be done in the clinical timeframe |
| 5 | How will the result change management? | Treatment, isolation, reporting, worker safety, trade implications | Determines whether testing is worth performing at all |

The fifth step is frequently omitted. If a test result will not alter the clinical or public health response, the test has no practical value regardless of its sensitivity and specificity. This is particularly relevant for zoonoses where treatment options in animals are limited. For *Coxiella burnetii*, the absence of treatment options in animals and limited approaches to prevention mean that testing is primarily useful for biosecurity planning and worker protection instead of individual animal therapy [Management of Coxiella burnetii infection in livestock populations and](https://pubmed.ncbi.nlm.nih.gov/30084178/).

## Documenting and Communicating Results

Test results for zoonotic agents carry obligations beyond the medical record. The veterinarian must document the reason for testing, the test used, the laboratory performing the test, the interpretation, and the actions taken. This documentation serves multiple purposes: it supports clinical reasoning, provides a basis for public health reporting where required, and creates a record that can be reviewed if a human case is subsequently identified.

Communication of results to the owner or producer must include the limitations of the test. A negative serological result in an animal tested during the window period does not exclude infection, and the owner should be advised of the need for repeat testing if clinical signs persist. For agents with occupational exposure risk, such as *Brucella* and *Coxiella*, the veterinarian should also communicate the implications for human health and recommend that at-risk individuals consult their own healthcare providers [Review of clinical and laboratory features of human brucellosis](https://pubmed.ncbi.nlm.nih.gov/17901634/).

The format of the report should distinguish between the laboratory's raw result, the veterinarian's interpretation, and the recommended follow-up. This distinction becomes critical when results are shared across sectors. The One Health framework emphasizes coordination among animal, human, and environmental health sectors for effective zoonotic disease management [WHO One Health Initiative](https://www.who.int/health-topics/one-health), and the diagnostic record is the primary vehicle for that coordination.

## When Testing Should Not Be Performed

There are circumstances where testing is actively counterproductive. Testing a healthy animal for a zoonotic agent without a clinical indication can produce a false positive that leads to unnecessary culling, trade restrictions, or owner anxiety. Testing during the window period can produce a false negative that provides false reassurance and delays appropriate biosecurity measures.

The decision to test should be based on a defined clinical question, not on the availability of a test. For agents with imperfect sensitivity, such as *Coxiella burnetii*, a negative result should not be used to discontinue biosecurity measures that were implemented on the basis of exposure risk [Management of Coxiella burnetii infection in livestock populations and](https://pubmed.ncbi.nlm.nih.gov/30084178/). Similarly, for *Fasciola* infection, antibody testing is the only tool available for diagnosis confirmation early in infection, but the presence of antibodies does not distinguish current from past infection, and stool microscopy is needed to confirm active infection in chronic cases [Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis,](https://pubmed.ncbi.nlm.nih.gov/33273878/).

The veterinarian's role includes advising when testing adds no value. In a low-prevalence population, the positive predictive value of a screening test is low, and confirmatory testing of every positive result may be required. The cost of that confirmatory testing should be weighed against the probability of disease before the screening test is ordered.

## Recognized Failure Modes in Zoonotic Test Interpretation

The most consequential failure in zoonotic diagnostic testing is not analytical error but interpretive error. A test result that is analytically correct can still mislead when its performance characteriztics do not match the clinical question. For Coxiella burnetii, the [consensus statement on management of coxiellosis in livestock populations](https://pubmed.ncbi.nlm.nih.gov/30084178/) notes that available diagnostic tests have limited sensitivity, which complicates both individual animal diagnosis and herd-level decisions. When a sensitive test is unavailable, a negative result cannot exclude infection, and repeated sampling or alternative test platforms become necessary.

A second failure mode is the inappropriate extrapolation of test performance across populations. Sensitivity and specificity are not fixed properties of a test. They vary with disease prevalence, stage of infection, vaccination status, and the reference standard used during validation. A serological assay validated in a naive population may perform differently in a vaccinated herd, where antibody responses blur the distinction between exposure and infection. The same principle applies across species. Tests validated in cattle may not perform identically in goats or sheep, and the [review of human brucellosis clinical and laboratory features](https://pubmed.ncbi.nlm.nih.gov/17901634/) emphasizes that serological interpretation must account for endemicity and prior exposure.

A third failure mode is the conflation of different diagnostic targets. Antibody detection, antigen detection, and nucleic acid amplification answer different questions. Antibody tests indicate past or present exposure and are subject to window periods. Antigen and molecular tests indicate current infection but may be negative if the organizm is sequestered or shed intermittently. For Fasciola infection, [current epidemiological status and strategies for diagnosis](https://pubmed.ncbi.nlm.nih.gov/33273878/) notes that antibody testing is the only reliable tool early in infection, whereas stool microscopy becomes useful only in chronic forms. Selecting a test without first defining whether the question is exposure, active infection, or shedding risk invites misinterpretation.

## Common Errors and Corrective Actions

Less experienced clinicians often overinterpret a single negative result in a high-risk exposure scenario. The corrective action is to establish the window period for the specific test and pathogen before drawing conclusions. For agents with prolonged or variable incubation, such as Brucella spp., a single early negative serology does not exclude infection, and repeat testing after an appropriate interval is indicated.

A second common error is the use of screening tests for confirmation. Screening assays are optimized for sensitivity and will produce false positives in low-prevalence populations. A positive screening result should trigger a confirmatory test with higher specificity, not a definitive diagnosis. This principle is well established in [toxoplasmosis serodiagnosis review](https://pubmed.ncbi.nlm.nih.gov/32457848/), which describes the dye test as the reference method and cautions that other assays vary in performance.

A third error is failure to account for vaccination history. Modified-live and killed vaccines can induce antibody responses that are indistinguishable from natural infection on some platforms. The corrective action is to document vaccination status before testing and to select assays or interpret results in light of that history.

## Limitations of the Current Evidence

The evidence base for zoonotic diagnostic test performance is uneven. For some pathogens, such as Toxoplasma gondii, multiple comparative studies exist. For others, particularly emerging or neglected zoonoses, validation data are sparse. The [comprehensive review of surveillance and response strategies for zoonotic diseases](https://pubmed.ncbi.nlm.nih.gov/39077041/) notes that diagnostic and surveillance gaps persist despite advances, and that the emergence of zoonoses continues to challenge prediction and prevention efforts.

Expert opinion differs on several points. One area of active debate is the role of PCR versus serology for herd-level screening in Coxiella burnetii. PCR detects shedding but misses seropositive, non-shedding animals. Serology detects exposure but cannot distinguish current from past infection. The [consensus statement on Coxiella burnetii management](https://pubmed.ncbi.nlm.nih.gov/30084178/) acknowledges that no single testing approach is optimal and that sampling strategy depends on the objective, whether that is identifying abortifacient risk, assessing environmental contamination, or monitoring a control program.

A second area of uncertainty is the clinical significance of low-level antibody titres in endemic regions. Some authorities treat any detectable titre as evidence of infection. Others require a fourfold rise between paired samples. The [human brucellosis review](https://pubmed.ncbi.nlm.nih.gov/17901634/) notes that fewer than 10% of human cases may be clinically recognized, which suggests that serological surveillance should be paired with a high index of clinical suspicion instead of relied upon alone.

## Escalation and Reporting

Referral or specialist consultation is warranted when test results conflict with clinical findings, when a result has public health implications beyond the individual patient, or when the diagnostic question requires a platform not available in the practice. Veterinary diagnostic laboratories can advise on test selection, sample handling, and interpretation, particularly for assays with complex performance characteriztics.

Regulatory reporting obligations vary by jurisdiction and by pathogen. Some zoonoses are notifiable in animals, in humans, or both. The [World Organization for Animal Health terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) define international reporting obligations for listed diseases, and the [CDC One Health and zoonotic disease resources](https://www.cdc.gov/one-health/index.html) provide guidance on cross-sector collaboration. Veterinarians should know which zoonoses are reportable in their region and should contact the relevant authority before results are disclosed to the owner, not after.

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
| --- | --- | --- |
| Negative serology in a clinically affected animal | Test performed during window period | Repeat testing after interval appropriate for the pathogen |
| Positive screening test, negative confirmatory test | False positive on screening assay | Review assay performance characteriztics and prevalence |
| Positive serology in a vaccinated animal | Vaccine-induced antibody | Document vaccination history, use DIVA assays if available |
| PCR positive, serology negative | Early infection or immunocompromise | Correlate with clinical signs and exposure history |
| Discordant results between laboratories | Different assay platforms or cut-offs | Request the reference method or standardize platforms |
| Intermittent shedding on PCR | Organizm sequestration or intermittent excretion | Repeat sampling at intervals, combine with serology |

## Frequently Asked Questions

### How Do I Choose a Test When Budget Constraints Limit the Panel?

Prioritize tests by clinical consequence instead of by cost alone. A negative result on a low-cost screening test with high sensitivity can rule out a high-risk zoonosis, whereas a cheap test with poor sensitivity creates false reassurance. For herd-level screening, pool samples or test a statistically valid subset instead of reducing panel quality. When resources are limited, focus on the zoonoses with the highest local prevalence and the most severe human consequences, then document the testing limitation in the medical record. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) provide guidance on surveillance design that can help justify targeted sampling strategies.

### What Should I Do When the Recommended Confirmatory Test Is Unavailable?

Use the best available alternative and state its limitations explicitly. If PCR is unavailable, paired serology with a fourfold rise in titer may substitute for acute infection confirmation, provided the assay has documented performance in the species tested. For agents like *Coxiella burnetii*, where available diagnostic tests have limited sensitivity, a negative result does not exclude infection, and management decisions should incorporate exposure risk and clinical signs [consensus guidance on coxiellosis management](https://pubmed.ncbi.nlm.nih.gov/30084178/). Contact a reference laboratory for specimen referral before abandoning the diagnostic plan. Record the substituted platform and its performance characteriztics in the patient record.

### How Does Test Interpretation Change When I Am Testing a Herd instead of an Individual?

Herd-level testing shifts the objective from individual diagnosis to prevalence estimation and risk classification. A test with moderate sensitivity may still be useful for herd screening because the cost of missing an individual infection is offset by identifying infected groups. Interpret apparent prevalence with knowledge of the test's sensitivity and specificity to estimate true prevalence. For agents with low within-herd prevalence, consider pooled sampling strategies. The [WHO One Health framework](https://www.who.int/health-topics/one-health) emphasizes that herd-level results inform population interventions, and the same test result may warrant different action depending on whether the question is individual patient safety or regional surveillance.

### What Information Must I Record When Documenting Zoonotic Test Results?

Record the test platform, laboratory, sample type, collection date relative to exposure and clinical onset, and the assay's reported sensitivity and specificity. Note the pretest probability used in interpretation and the resulting posttest probability. Document any deviation from the recommended testing protocol and the reason for it. Record the interpretation in language that distinguishes infection from active shedding and clinical disease. The [CDC One Health resources](https://www.cdc.gov/one-health/index.html) advise that complete documentation supports both patient care and public health follow-up. Include the communication of results to the client and any reporting obligations to public health authorities, even if the obligation is only suspected.

### How Do I Explain a Discordant Result to a Client or Referring Veterinarian?

Explain that discordant results occur when two tests disagree and that this does not necessarily indicate laboratory error. Describe the window period, where an early infection may be negative on antibody testing but positive on PCR, or the reverse in a resolved infection. Use likelihood ratios to show how the pretest probability shifts with each result. For *Fasciola* infection, antibody testing is the only reliable tool early in infection, while stool microscopy becomes useful only in chronic stages [review of fascioliasis diagnosis](https://pubmed.ncbi.nlm.nih.gov/33273878/). Recommend a repeat test at an appropriate interval or a third platform, and frame the uncertainty as a test timing issue instead of a testing failure.

### When Is It Defensible to Treat Without Confirming the Zoonosis?

Treatment without confirmation is defensible when the zoonotic risk to humans is immediate, the disease is clinically characteriztic, and the delay for confirmatory testing would worsen the outcome. This applies most clearly in acute febrile illness with known occupational or environmental exposure. Collect diagnostic samples before starting treatment, because antimicrobial therapy can suppress culture and seroconversion. For brucellosis, fewer than 10% of human cases may be clinically recognized, so a high index of suspicion justifies empirical treatment while awaiting serology [review of human brucellosis features](https://pubmed.ncbi.nlm.nih.gov/17901634/). Document the clinical reasoning, the samples collected, and the planned confirmatory testing in the record.

## Related Clinical & Scientific Guides

* [Wildlife Disease Surveillance: Designing and Implementing a One Health Program](/knowledge/veterinary-medicine/veterinary-public-health/wildlife-disease-surveillance-designing-implementing-one-health-program)
* [Biosecurity Risk Assessment for Livestock Operations: A Practical Framework](/knowledge/veterinary-medicine/veterinary-public-health/biosecurity-risk-assessment-livestock-operations-practical-framework)
* [Rabies Post-Exposure Prophylaxis in Veterinary Personnel](/knowledge/veterinary-medicine/veterinary-public-health/rabies-post-exposure-prophylaxis-in-veterinary-personnel)


## References and Further Reading

- [Management of Coxiella burnetii infection in livestock populations and the associated zoonotic risk: A consensus statement.](https://pubmed.ncbi.nlm.nih.gov/30084178/). 2018.
- [Molecular biology and pathogenesis of hepatitis E virus.](https://pubmed.ncbi.nlm.nih.gov/19208971/). 2008.
- [Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control.](https://pubmed.ncbi.nlm.nih.gov/33273878/). 2020.
- [Surveillance and response strategies for zoonotic diseases: a comprehensive review.](https://pubmed.ncbi.nlm.nih.gov/39077041/). 2023.
- [Review on the Current Trends of Toxoplasmosis Serodiagnosis in Humans.](https://pubmed.ncbi.nlm.nih.gov/32457848/). 2020.
- [Review of clinical and laboratory features of human brucellosis.](https://pubmed.ncbi.nlm.nih.gov/17901634/). 2007.
- [WHO One Health Initiative](https://www.who.int/health-topics/one-health). WHO.
- [CDC One Health and Zoonotic Disease Resources](https://www.cdc.gov/one-health/index.html). CDC.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Zoonotic Disease Risk Assessment in Veterinary Practice](/knowledge/veterinary-medicine/veterinary-public-health/zoonotic-disease-risk-assessment-in-veterinary-practice)
- [Veterinary Epidemiology: Study Designs for Zoonotic Disease Research](/knowledge/veterinary-medicine/veterinary-public-health/veterinary-epidemiology-study-designs-zoonotic-disease-research)
- [Zoonotic Disease Risk Communication in Veterinary Practice](/knowledge/veterinary-medicine/veterinary-public-health/zoonotic-disease-risk-communication-in-veterinary-practice)
- [Diagnostic Prioritization in Acute Febrile Illness of Zoonotic Origin](/knowledge/veterinary-medicine/veterinary-public-health/diagnostic-prioritization-acute-febrile-illness-zoonotic-origin)
- [Zoonotic Disease Surveillance in Animal Shelters: Methods and Challenges](/knowledge/veterinary-medicine/veterinary-public-health/zoonotic-disease-surveillance-in-animal-shelters-methods-and-challenges)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.